BLOOMINGTON, Ind.--(BUSINESS WIRE)--Minocycline/rifampin-impregnated catheters are a critical component in modern health care practices designed to eliminate potentially fatal catheter-related bloodstream infections (CRBSIs) that affect 250,000 Americans a year, according to recently released clinical data from the Society of Critical Care Medicine’s 38th Critical Care Congress. The first set of data reveal that an over-the-wire exchange of an infected central venous catheter (CVC) for a CVC impregnated with minocycline and rifampin, which are two antibiotic drugs that act together to dramatically reduce the risk of infections, can more quickly help eliminate an existing infection in cancer patients than currently recommended procedures. The second, a first ever head-to-head study that lasted 46 months, revealed that minocycline/rifampin-impregnated CVCs are nearly twice as effective at preventing CRBSIs than second generation CVCs coated with a chlorhexidine/silver sulfadiazine solution.
